Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi in a pre-Series B+ financing round, with the investment being solely provided by Cash Capital.
Company Background and Pipeline
Founded in 2018, Gene Cradle has established itself as a leader in the development and manufacturing of gene therapies targeting a range of genetic disorders. The company currently boasts three AAV vector injectables, all classified as Category 1 biologics, which have entered the clinical trials stage. These therapies are aimed at treating hereditary hypertriglyceridemia, spinal muscular atrophy (SMA), and Pompe disease, respectively.
Focus on Genetic Neuromuscular and Metabolic Diseases
Gene Cradle is dedicated to addressing genetic neuromuscular diseases, genetic metabolic diseases, lysosomal diseases, and ophthalmic diseases. The company’s first gene therapy for SMA is ahead of similar products in the clinical pipeline in China, positioning Gene Cradle at the forefront of gene therapy innovation for these conditions.-Fineline Info & Tech
